Download Sample, Atrial Fibrillation (Afib) is Gaining Traction as a Result of High Prevalence of Hypertension & Obesity
Hypertension and obesity are the most common causes of cardiovascular disease, particularly atrial fibrillation. As per the Framingham Heart Study, hypertension was related with 14% of the atrial fibrillation risks, and obesity elevated the chance of development of paroxysmal atrial fibrillation to persistent atrial fibrillation by 45% to 50%. Due to socioeconomic variables such as lifestyle-induced dietary and other habits, the prevalence of these conditions is increasing. According to UCSF Health, approximately 60% of Americans aged 20 and older are overweight, with one-quarter being obese. Obesity prevalence has nearly tripled globally and likely to continue to increase in the future. According to the WHO, hypertension affects an estimated 1.28 billion individuals aged 30-79 years globally, with the majority (two-thirds) located in low- and middle-income countries. An estimated 46% of individuals with hypertension are unaware of their condition. The rising prevalence of these conditions is expected to boost the global atrial fibrillation (Afib) market throughout the forecast period.
However, technological advancements in diagnostic technologies such as electrocardiography (ECG), Holter monitors, and implantable cardiac monitors have transformed the early identification and intervention and diagnosis of atrial fibrillation (AFib). ECGs offer fast and non-invasive evaluations, whereas Holter monitors provide ongoing monitoring of heart rhythm for longer durations, detecting occasional AFib episodes that may be missed otherwise. Implantable devices offer continuous monitoring for an extended period, providing immediate access to heart rhythm data for healthcare professionals, enabling quick intervention and customized treatment strategies. These technologies work together to increase patient knowledge, allow for prompt medical interventions, and enhance long-term care results for AFib patients.
However, technological advancements in diagnostic technologies such as electrocardiography (ECG), Holter monitors, and implantable cardiac monitors have transformed the early identification and intervention and diagnosis of atrial fibrillation (AFib). ECGs offer fast and non-invasive evaluations, whereas Holter monitors provide ongoing monitoring of heart rhythm for longer durations, detecting occasional AFib episodes that may be missed otherwise. Implantable devices offer continuous monitoring for an extended period, providing immediate access to heart rhythm data for healthcare professionals, enabling quick intervention and customized treatment strategies. These technologies work together to increase patient knowledge, allow for prompt medical interventions, and enhance long-term care results for AFib patients.
Promising Clinical Trial Results for Atrial Fibrillation Treatment are Fueling Market Expansion
A novel and promising therapeutic option for atrial fibrillation (Afib) is combination pharmaceutical therapy. In clinical studies, the combination pharmaceutical treatment showed favourable results, and it might help meet unmet medical requirements in people with atrial fibrillation. This aspect is expected to boost the global market for atrial fibrillation (Afib). Furthermore, research on animals for combination treatment produced favourable and synergistic anti-arrhythmic results. The clinical studies including Multaq and Ranexa were disclosed at the Boston Atrial Fibrillation Symposium. The HARMONY clinical study involved around 150 individuals with non-permanent atrial fibrillation and pacemakers installed. This study's preclinical findings imply that this combination treatment is well positioned in the present anti-arrhythmic drugs segment, particularly in terms of safety and effectiveness.
Additionally, preventing strokes is a key priority when treating atrial fibrillation (AFib) due to its strong link to higher risk of strokes. Novel oral anticoagulants (NOACs) provide efficient stroke prevention by preventing blood clot formation without requiring frequent monitoring, unlike traditional warfarin therapy. Furthermore, LAAC devices offer a different method for preventing strokes in AFib patients at high risk of bleeding issues from anticoagulants. These treatment advances strive to improve patient results by decreasing the occurrence of disabling strokes linked to AFib.
Additionally, preventing strokes is a key priority when treating atrial fibrillation (AFib) due to its strong link to higher risk of strokes. Novel oral anticoagulants (NOACs) provide efficient stroke prevention by preventing blood clot formation without requiring frequent monitoring, unlike traditional warfarin therapy. Furthermore, LAAC devices offer a different method for preventing strokes in AFib patients at high risk of bleeding issues from anticoagulants. These treatment advances strive to improve patient results by decreasing the occurrence of disabling strokes linked to AFib.
Recent Trends in Atrial Fibrillation Market:
- Advanced technologies for AFib management, including more precise and effective catheter ablation techniques
- NOACs continue to gain popularity over warfarin due to their comparable efficacy in stroke prevention, fewer drug interactions
- Improved diagnostic tools, such as mobile ECG devices and wearable monitors, facilitate early detection of AFib episodes
- There is growing adoption of personalized treatment approaches based on patient-specific factors, including genetic profiling and biomarkers
Explore Our Breakthrough Market Segmentation and Personalize it to Meet Your Business Needs…!
Regulations for Product Approval from CE, FDA & European Medicines Agency Are Strict and Limit Market Expansion
The FDA classifies atrial fibrillation devices such as defibrillators, implantable pacemakers, and catheters as class III high risk medical devices. As a result, before getting clearance, these devices must pass stringent safety and effectiveness research studies. Furthermore, these devices need to obtain premarket clearance, which is a costly and time-consuming process. Atrial fibrillation medications are not exempt from these tough standards and must thus undergo rigorous safety and effectiveness testing. Failure to follow the FDA and European Medicines Agency requirements will result in a product recall or the termination of a clinical study.
Furthermore, the management of atrial fibrillation (AFib) is complicated and involves more than just taking medication. It includes diverse treatment strategies such as using anticoagulants to prevent strokes, controlling heart rate, and restoring normal heart rhythm. Healthcare providers must carefully consider individual patient factors and preferences in this complex landscape, which can make treatment decisions more challenging. Furthermore, it is essential for patients to follow these complex treatment plans, which can be difficult due to the multiple medications and lifestyle changes involved, affecting the success of therapy and overall results in managing AFib.
Furthermore, the management of atrial fibrillation (AFib) is complicated and involves more than just taking medication. It includes diverse treatment strategies such as using anticoagulants to prevent strokes, controlling heart rate, and restoring normal heart rhythm. Healthcare providers must carefully consider individual patient factors and preferences in this complex landscape, which can make treatment decisions more challenging. Furthermore, it is essential for patients to follow these complex treatment plans, which can be difficult due to the multiple medications and lifestyle changes involved, affecting the success of therapy and overall results in managing AFib.
Strategic Development by Key Players Remarkable for Atrial Fibrillation Market
The atrial fibrillation market needs new products with better effectiveness in controlling rhythm and rate, reducing side effects such as bleeding risks from anticoagulants, improving patient adherence with easier treatment plans or modern delivery methods, and meeting gaps in stroke prevention and symptom management for improved treatment results. For Instance, in January 2024, Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) approval for the FARAPULSE Pulsed Field Ablation (PFA) System. The FARAPULSE PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (intermittent) atrial fibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment. In Addition, Abbott announced in February 2023 that it had received clearance from the European Union and the US Food and Drug Administration (FDA) for its TactiFlex Ablation Catheters and Sensor Enabled. These are flexible tip ablation catheters with contact force sensors. These products are designed to treat patients who have irregular heart rhythms such as atrial fibrillation (Afib). FlexAbility Ablation Catheters and Sensor Enabled has been given enhanced indication2 by the US FDA to treat patients with a complicated cardiac disease. Medtronic obtained CE Mark authorization in March 2023 for its Ablation System with Affera Mapping, which uses the Affera Prism-1 Mapping Software and Sphere-9 Catheter to treat atrial arrhythmias. This device combines pulsed field ablation, radiofrequency and a high-density mapping catheter to offer real-time feedback as well as precise mapping and ablation of abnormal cardiac rhythms, ushering in a new era in electrophysiology.
Know Your Competitors and Strengthen Market Share Effectively
Presence of Major Market Players & Availability of Beneficial Insurance Policies All Contribute to Market Expansion
North America generated the largest amount of revenue in the atrial fibrillation (Afib) market in 2022. This is mostly due to the region's increasing patient pool and the presence of significant players. Within the North American region, the United States is likely to dominate market growth. According to statistics provided by the CDC, in September 2023, it was estimated that 13.1 million Americans would suffer from atrial fibrillation by the year 2030. With the growing geriatric population, it is anticipated that market demand will increase in the coming years. The presence of major players in the country, advancements in technology, and the availability of favourable insurance policies are all contributing to the market's growth in the United States. As a result of the aforementioned factors, the market in this region is anticipated to grow over the forecast period.
Searching for a Country or Region-Specific Report?
Unlock industry complexities with reports crafted for selected countries and regions at Reduced Cost
The report provides a detailed overview of the atrial fibrillation (Afib) market insights in regions including North America, Latin America, Europe, Asia-Pacific, Oceania, and the Middle East and Africa. The country-specific assessment for atrial fibrillation (Afib) market has been offered for all regional market share, along with forecasts, market scope estimates, price point assessment, and impact analysis of prominent countries and regions. Throughout this market research report, Y-o-Y growth and CAGR estimates are also incorporated for every country and region, to provide a detailed view of the atrial fibrillation (Afib) market. These Y-o-Y projections on regional and country-level markets brighten the political, economic and business environment outlook, which are anticipated to have a substantial impact on the growth of the atrial fibrillation (Afib) market. Some key country and region included in the atrial fibrillation (Afib) market report as follows:
| Regions | Countries |
|---|---|
| North America | United States, Canada |
| Latin America | Brazil, Mexico, Argentina, Colombia, Chile, Rest of Latin America |
| Europe | Germany, United Kingdom, France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Austria, Norway, Denmark, Finland, Ireland, Czech Republic, Rest of Europe |
| Asia Pacific | China, India, Japan, South Korea, Australia & New Zealand, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia Pacific |
| Middle East and Africa | GCC Countries, South Africa, Egypt, Turkey, Morocco, Israel, Iran, Kenya, Nigeria, Rest of MEA |
Atrial Fibrillation Market Research Report Covers In-depth Analysis on:
- Atrial fibrillation market detailed segments and segment-wise market breakdown
- Atrial fibrillation market dynamics (Recent industry trends, drivers, restraints, growth potential, opportunities in atrial fibrillation industry)
- Current, historical and forthcoming 10 years market valuation in terms of atrial fibrillation market size (US$ Mn), share (%), Y-o-Y growth rate, CAGR (%) analysis
- Atrial fibrillation market demand analysis
- Atrial fibrillation market regional insights with region-wise market breakdown
- Competitive analysis – key companies profiling including their market share, product offerings, and competitive strategies.
- Latest developments and innovations in atrial fibrillation market
- Regulatory landscape by key regions and key countries
- Atrial fibrillation market sales and distribution strategies
- A comprehensive overview of parent market
- A detailed viewpoint on atrial fibrillation market forecast by countries
- Mergers and acquisitions in atrial fibrillation market
- Essential information to enhance market position
- Robust research methodology
- Frequently Asked Questions -
What are the key drivers influencing atrial fibrillation (Afib) market?
Major drivers include increasing prevalence of Afib, advancements in treatment technologies and growing aging population, which fuels demand for effective therapeutic solutions.
What are the forecasted trends for the atrial fibrillation (Afib) market over the next decade?
The report forecasts continued growth due to technological advancements, increased awareness and rising healthcare investments in Afib management and treatment.
How does the report address regional differences in atrial fibrillation (Afib) market?
The report provides a regional analysis, highlighting key trends, market size, and growth potential across different geographical areas, including North America, Europe and Asia-Pacific.
